Clinical Pharmacology of Vancomycin in Pediatrics
Pharmacy and Drug Development · 2022
DOI: 10.58489/2836-2322/009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy and Drug Development, 2022. Verfasst von Gudisa Bereda. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Vancomycin plays an indispensable therapeutic function in managing severe infections caused by MRSA in the children population. Preponderance children dosing references for vancomycin recommend a daily dose of 40 mg/kg/day for empirical treatment, while a dose of 60 mg/kg/day is recommended for CNS infections. Vancomycin is absorbed in fewer amounts through PO in GIT, it is thus IV administered. IV infusions of vancomycin perhaps cause pain, phlebitis, erythema, urticaria, flushing, hypotension, tachycardia and the red man syndrome. Coincident administration of vancomycin with amphotericin-B, NSAIDs, aminoglycosides, cisplatin and other nephrotoxic agents perhaps exaggerated the risk of nephrotoxicity. Concomitant administration of vancomycin and furosemide, aminoglycosides, ethacrynic acid, etc perhaps increase the risk of ototoxicity. Coadministration of vancomycin and vecuronium increases the risk of neuromuscular blockage. If vancomycin and zidovudine are administered together, they increase the risk of neutropenia.
Zitieren
APA
Bereda, G. (2022). Clinical Pharmacology of Vancomycin in Pediatrics. Pharmacy and Drug Development. https://doi.org/10.58489/2836-2322/009
Vancouver
Bereda G. Clinical Pharmacology of Vancomycin in Pediatrics. Pharmacy and Drug Development. 2022. doi:10.58489/2836-2322/009
BibTeX
@article{Bereda2022,
author = {Bereda, Gudisa},
title = {Clinical Pharmacology of Vancomycin in Pediatrics},
journal = {Pharmacy and Drug Development},
year = {2022},
doi = {10.58489/2836-2322/009}
}
EUVIMED